Speakers

Dan Shelly

Vice President of Business Development and Alliances • Prescient Therapeutics

Daniel Shelly, Ph.D., MBA is Vice President of Business Development and Alliances at Prescient Therapeutics where he is responsible for advancing a next-generation, modular, and post-infusion controllable CAR-Immune cell therapy platform along with small molecule targeted therapies. Previously, he was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force. He has over 19 years of biopharmaceutical BD licensing and alliance management experience. He is also an adjunct professor in the Master’s in Clinical Drug Development program at the University of Cincinnati’s College of Pharmacy.

Also Speaking

Image

Wilson Bryan

Director, Office of Tissues and Advanced Therapies • FDA
31 October 2022
Image

Carl H. June

Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine • University of Pennsylvania
18 November 2022
Image

Jenny Holt

Senior Vice President, Programme and Portfolio Management • Ray Therapeutics
31 October 2022

Event Info

Image

Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.
21 March 2023
Image

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.
6 January 2023